The efficacy of rituximab in high-risk renal transplant recipients

Motoo Araki; Koichiro Wada; Yosuke Mitsui; Risa Kubota; Takashi Yoshioka; Yuichi Ariyoshi; Yasuyuki Kobayashi; Masashi Kitagawa; Katsuyuki Tanabe; Hiroshi Sugiyama; Jun Wada; Masami Watanabe; Toyohiko Watanabe; Katsuyuki Hotta; Yasutomo Nasu

The efficacy of rituximab in high-risk renal transplant recipients

Motoo Araki, Koichiro Wada, Yosuke Mitsui, Risa Kubota, Takashi Yoshioka, Yuichi Ariyoshi, Yasuyuki Kobayashi, Masashi Kitagawa, Katsuyuki Tanabe, Hiroshi Sugiyama, Jun Wada, Masami Watanabe, Toyohiko Watanabe, Katsuyuki Hotta, Yasutomo Nasu

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.

Original language	English
Pages (from-to)	295-298
Number of pages	4
Journal	Acta medica Okayama
Volume	70
Issue number	4
Publication status	Published - 2016

Keywords

End-stage renal disease
Immunosuppression
Kidney transplantation

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{424a17cc46ba4e3e863d7e5c801baced,

title = "The efficacy of rituximab in high-risk renal transplant recipients",

abstract = "Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.",

keywords = "End-stage renal disease, Immunosuppression, Kidney transplantation",

author = "Motoo Araki and Koichiro Wada and Yosuke Mitsui and Risa Kubota and Takashi Yoshioka and Yuichi Ariyoshi and Yasuyuki Kobayashi and Masashi Kitagawa and Katsuyuki Tanabe and Hiroshi Sugiyama and Jun Wada and Masami Watanabe and Toyohiko Watanabe and Katsuyuki Hotta and Yasutomo Nasu",

note = "Funding Information: The authors wish to acknowledge and thank the coordinators and all other investigators who have contributed to this study. This protocol has been written with support from the Center for Innovative Clinical Medicine, Okayama University Hospital. Publisher Copyright: {\textcopyright} 2016 by Okayama University Medical School.",

year = "2016",

language = "English",

volume = "70",

pages = "295--298",

journal = "Acta medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "4",

}

TY - JOUR

T1 - The efficacy of rituximab in high-risk renal transplant recipients

AU - Araki, Motoo

AU - Wada, Koichiro

AU - Mitsui, Yosuke

AU - Kubota, Risa

AU - Yoshioka, Takashi

AU - Ariyoshi, Yuichi

AU - Kobayashi, Yasuyuki

AU - Kitagawa, Masashi

AU - Tanabe, Katsuyuki

AU - Sugiyama, Hiroshi

AU - Wada, Jun

AU - Watanabe, Masami

AU - Watanabe, Toyohiko

AU - Hotta, Katsuyuki

AU - Nasu, Yasutomo

N1 - Funding Information: The authors wish to acknowledge and thank the coordinators and all other investigators who have contributed to this study. This protocol has been written with support from the Center for Innovative Clinical Medicine, Okayama University Hospital. Publisher Copyright: © 2016 by Okayama University Medical School.

PY - 2016

Y1 - 2016

N2 - Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.

AB - Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.

KW - End-stage renal disease

KW - Immunosuppression

KW - Kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=84984858046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984858046&partnerID=8YFLogxK

M3 - Article

C2 - 27549676

AN - SCOPUS:84984858046

SN - 0386-300X

VL - 70

SP - 295

EP - 298

JO - Acta medica Okayama

JF - Acta medica Okayama

IS - 4

ER -

The efficacy of rituximab in high-risk renal transplant recipients

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this